Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Michigan: - Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
- Trinity Health Medical Center - Brighton — Brighton, Michigan
- University of Michigan - Brighton Center for Specialty Care — Brighton, Michigan
- Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Michigan: - Veteran's Administration Medical Center - Ann Arbor — Ann Arbor, Michigan
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
- McLaren Cancer Institute-Bay City — Bay City, Michigan
- University of Michigan - Brighton Center for Specialty Care — Brighton, Michigan
- Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Michigan: - Saint Joseph Mercy Hospital — Ann Arbor, Michigan
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Saint Joseph Mercy Brighton — Brighton, Michigan
- Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
- Saint Joseph Mercy Canton — Canton, Michigan
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Michigan: - Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital — Chelsea, Michigan
- OSF Saint Francis Hospital and Medical Group — Escanaba, Michigan
- Cancer Hematology Centers - Flint — Flint, Michigan
Phase 3 Recruiting Academic/Other
This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07200830
Sites in Michigan: - Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
- Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
- Henry Ford Macomb Hospital-Clinton Township — Clinton Township, Michigan
- Henry Ford Medical Center-Fairlane — Dearborn, Michigan
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in Michigan: - Michigan Institute of Urology, PC — Troy, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or dea…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Michigan: - Profound Research LLC at Cancer and Leukemia Center — Sterling Heights, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Michigan: - University of Michigan Health System — Ann Arbor, Michigan
- Henry Ford Cancer Detroit — Detroit, Michigan
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in Michigan: - University of Michigan ( Site 0005) — Ann Arbor, Michigan
- Henry Ford Hospital ( Site 0035) — Detroit, Michigan
- Cancer and Hematology Centers of Western Michigan ( Site 0015) — Grand Rapids, Michigan
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Michigan: - Henry Ford Hospital ( Site 0015) — Detroit, Michigan
Phase 3 Recruiting Industry
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Sponsor: Amgen
NCT ID: NCT07213674
Sites in Michigan: - Barbara Ann Karmanos Cancer Institute — Lansing, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Sites in Michigan: - BAMF Health — Grand Rapids, Michigan
- Profound Research LLC — Royal Oak, Michigan
- William Beaumont Hospital — Royal Oak, Michigan
Phase 3 Recruiting Industry
Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or enzalutamid…
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT07723248
Sites in Michigan: - Cancer And Hematology Centers Of Western Michigan — Holland, Michigan
Phase 2 Recruiting Academic/Other
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in Michigan: - Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital — Chelsea, Michigan
- University of Michigan Health - Sparrow Lansing — Lansing, Michigan
- Trinity Health Saint Mary Mercy Livonia Hospital — Livonia, Michigan
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Michigan: - Henry Ford Health — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06800313
Sites in Michigan: - South Texas Accelerated Research Therapeutics, LLC (START) — Grand Rapids, Michigan
Phase 2 Recruiting Industry
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on…
Sponsor: Zenith Epigenetics
NCT ID: NCT04986423
Sites in Michigan: - University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
Phase 2 Recruiting Industry
The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurat…
Sponsor: Sun Pharmaceutical Industries Limited
NCT ID: NCT05422911
Sites in Michigan: - VA Ann Arbor Healthcare System — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.
Sponsor: AstraZeneca
NCT ID: NCT07181161
Sites in Michigan: - Research Site — Ann Arbor, Michigan
- Research Site — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
Sponsor: MBrace Therapeutics
NCT ID: NCT07145255
Sites in Michigan: - START, Midwest — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Industry
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT04868604
Sites in Michigan: - BAMF Health — Grand Rapids, Michigan
Phase 2 Recruiting Industry
The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.
Sponsor: Syntrix Biosystems, Inc.
NCT ID: NCT06228053
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 …
Sponsor: AstraZeneca
NCT ID: NCT07192614
Sites in Michigan: - Research Site — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conduct…
Sponsor: Tanabe Pharma America, Inc.
NCT ID: NCT06943521
Sites in Michigan: - START Midwest — Grand Rapids, Michigan
Phase 2 Recruiting Federal
This trial tests if the combination of comprehensive metastasis directed therapy delivered by a precision form of external beam radiotherapy (stereotactic ablative radiotherapy), combined with PSMA targeted radiopharmaceutical therapy and …
Sponsor: VA Office of Research and Development
NCT ID: NCT06084338
Sites in Michigan: - VA Ann Arbor Healthcare System, Ann Arbor, MI — Ann Arbor, Michigan